Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11.

Michael D Jain,David B Miklos,Caron A Jacobson,John M Timmerman,Jennifer Sun,Jenny Nater,Xiang Fang,Ankit Patel,Madison Davis,Darren Heeke,Tan Trinh,Mike Mattie, Frank Neumann,Jenny J Kim, Christina To,Simone Filosto,Ran Reshef

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览22

暂无评分

摘要

Utomilumab-mediated 4-1BB agonism combined with axi-cel therapy had a manageable safety profile. Dual 4-1BB and CD28 costimulation is a feasible therapeutic approach that may enhance CAR T-cell expansion in patients with LBCL.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要